Get the Stockscreener App
4.67
1.97%
0.09
4 D Molecular Therapeutics Inc stock is traded at $4.67, with a volume of 1.08M.
It is up +1.97% in the last 24 hours and down -25.99% over the past month.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
See More
Previous Close:
$4.58
Open:
$4.58
24h Volume:
1.08M
Relative Volume:
1.29
Market Cap:
$215.88M
Revenue:
$20.72M
Net Income/Loss:
$-100.84M
P/E Ratio:
-1.7556
EPS:
-2.66
Net Cash Flow:
$-78.56M
1W Performance:
-4.30%
1M Performance:
-25.99%
6M Performance:
-67.57%
1Y Performance:
-72.58%
1-Day Range:
$4.48
$4.685
1-Week Range:
$4.48
$5.15
52-Week Range:
$4.48
$36.25
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Name
4 D Molecular Therapeutics Inc
Sector
Industry
Phone
(510) 505-2680
Address
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
4.67 | 215.88M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-21-24 | Initiated | Morgan Stanley | Underweight |
| Sep-23-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Apr-15-24 | Initiated | Barclays | Overweight |
| Feb-07-24 | Resumed | Goldman | Buy |
| Oct-26-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-18-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-18-22 | Initiated | H.C. Wainwright | Buy |
| Nov-15-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-12-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-22-22 | Initiated | Jefferies | Buy |
| Jan-04-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Evercore ISI | Outperform |
| Jan-05-21 | Initiated | Goldman | Neutral |
View All
4 D Molecular Therapeutics Inc Stock (FDMT) Latest News
Assenagon Asset Management S.A. Sells 889,884 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc.FDMT - PR Newswire
FDMT stock touches 52-week low at $4.48 amid market challenges - MSN
4D Molecular Therapeutics' (FDMT) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Weiss Ratings Reiterates Sell (D-) Rating for 8X8 (NASDAQ:EGHT) - Defense World
Weiss Ratings Reiterates “Sell (D-)” Rating for 89bio (NASDAQ:ETNB) - Defense World
Weiss Ratings Reaffirms “Sell (D-)” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
JPMorgan Chase & Co. Trims Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Equities Analysts Set Expectations for FDMT FY2029 Earnings - Defense World
FY2024 Earnings Estimate for FDMT Issued By Leerink Partnrs - Defense World
FY2029 Earnings Estimate for FDMT Issued By HC Wainwright - MarketBeat
Leerink Partnrs Has Bullish Outlook for FDMT FY2024 Earnings - MarketBeat
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Raised by Barclays PLC - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Lowered to “Market Perform” Rating by BMO Capital Markets - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given Buy Rating at HC Wainwright - Defense World
4D Molecular Therapeutics' SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Morgan Stanley Lowers 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $6.00 - MarketBeat
4D Molecular Therapeutics stock hits 52-week low at $5.2 - Investing.com India
4D Molecular downgraded at BMO on limited population for wet AMD candidate - MSN
4D Molecular Therapeutics (NASDAQ:FDMT) Stock Rating Lowered by BMO Capital Markets - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - MarketBeat
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 6 Analysts - Benzinga
Leerink cuts 4D Molecular Therapeutics price target following pipeline updates - Investing.com Australia
Leerink cuts 4D Molecular Therapeutics price target following pipeline updates By Investing.com - Investing.com South Africa
BMO Capital downgrades 4D Molecular Therapeutics stock to Market Perform, cites challenges - Investing.com Canada
BMO Capital downgrades 4D Molecular Therapeutics stock to Market Perform, cites challenges By Investing.com - Investing.com South Africa
4D Molecular Therapeutics refocuses on key drug candidates By Investing.com - Investing.com Australia
4D Molecular, FDA agree on phase 3 design for DME candidate - Seeking Alpha
FDMT4D Molecular Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
4D Molecular Therapeutics refocuses on key drug candidates - Investing.com India
4D Molecular Therapeutics Streamlines Pipeline, Advances Key Eye Disease & CF Programs with $506M Cash - StockTitan
Scrip Asks… What Does 2025 Hold For Biopharma? Part 1: The State Of The Biopharma Industry - News & Insights
4D Molecular's DME Drug Shows 86% Injection Reduction, Strong Vision Gains in Clinical Trial - StockTitan
Brokerages Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Target Price at $42.56 - Defense World
Brokerages Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Price Target at $42.56 - MarketBeat
Geode Capital Management LLC Sells 24,346 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Barclays PLC Has $1.24 Million Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics stock hits 52-week low at $5.57 By Investing.com - Investing.com Canada
Fmr LLC Sells 1,012,123 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Analyzing Scholar Rock (NASDAQ:SRRK) and 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
Critical Review: 4D Molecular Therapeutics (NASDAQ:FDMT) & Candel Therapeutics (NASDAQ:CADL) - Defense World
State Street Corp Boosts Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) dropped from S&P Biotechnology Select Industry Index - Marketscreener.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
What 5 Analyst Ratings Have To Say About 4D Molecular Therapeutics - Benzinga
Bank of America Has Lowered Expectations for 4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price - MarketBeat
Short Interest in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Increases By 8.8% - MarketBeat
4DMT Announces Landmark Publication of 4D-150 Preclinical - GlobeNewswire
4D Molecular's R100 Vector Shows 10X Potency Breakthrough in Landmark Eye Disease Study - StockTitan
4D Molecular Therapeutics stock hits 52-week low at $6.69 By Investing.com - Investing.com Canada
4D Molecular Therapeutics issues pre-funded warrant to RA Capital - Investing.com
4 D Molecular Therapeutics Inc Stock (FDMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):